Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

This study has been completed.
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company ) Identifier:
First received: October 1, 2002
Last updated: July 27, 2016
Last verified: July 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2006
  Estimated Primary Completion Date: No date given